World Health Organization Issues Concern Over Acute Scarcity of Weight-Loss Jabs

Under one in 10 individuals that would benefit from weight-loss injections like Wegovy can access them, states the World Health Organization as it issues its initial advice on the drugs.

Given over a billion individuals worldwide currently living with obesity, it is calling for broader and more equitable availability to this class of drugs.

According to projections, more than two billion are projected to be obese by 2030 unless action is taken.

"The new guidelines acknowledges that excess weight is a chronic disease that can be addressed with comprehensive and ongoing care," remarked its chief Tedros Adhanom Ghebreyesus.

High costs, insufficient output, and distribution challenges are significant hurdles to widespread availability to the treatments that can aid individuals in losing considerable weight, says the body.

Weight-Loss Drug Supply Crisis

Even under the present most optimistic case, the manufacturing of these medications might only reach approximately 100 million people – less than 10% of eligible patients, per the WHO.

The recommendation calls on countries and companies to increase availability, through approaches like patent sharing.

A patent on semaglutide – the core component of a leading brand – is scheduled to end in several nations in 2026.

The Way Weight-Loss Drugs Operate

These medications mimick a natural hormone to reduce digestion speed, reduce hunger and enhance satiety so people reduce food intake.

Individuals commonly begin shedding pounds after several weeks of commencing the once-weekly jabs.

Research points to people may regain a significant portion after a year of stopping the treatment, because their usual hunger resume.

Being carrying excess weight raises your chance for developing health problems, such as type 2 diabetes, cardiovascular issues, brain attack, and certain malignancies.

Excess weight impacts individuals in all nations and was responsible for millions of fatalities worldwide in 2024, as per the health agency.